Table 2.
Changes of clinical symptoms and theophylline metabolism in patients with severe-type asthma
| Case | Age (yr) | Sex | Before EM | 6 months after EM |
|---|---|---|---|---|
| 1 | 2 | F | Severe attack:1/1 month | Severe attack:1/6 months |
| 2 | 7 | M | Severe attack:1/2 months %FEV1.0 120% | Moderate attack:1/6 months %FEV1.0 145% |
| 3 | 9 | M | Moderate attack:1/2 wk %FEV1.0 55% | Moderate attack:1/2 months %FEV1.0 77% |
| 4 | 13 | M | Moderate attack:1/1 month %FEV1.0 75% | Moderate attack:1/6 months %FEV1.0 83% |
| TDM\case | 1 | 2 | 3 | Mean |
|---|---|---|---|---|
| CL (l/kg/h) | 0.094/0.077 | 0.093/0.055 | 0.092/0.054 | 0.093/0.062 |
| t1/2 (h) | 5.4/6.6 | 6.2/12.7 | 7.3/10.7 | 6.3/9.9 |
| AUC (μg/h/ml) | 99/120 | 247/418 | 160/247 | 169/262 |
| Cmin (μg/ml) | 3.0/8.2 | 7.8/15.1 | 3.5/9.2 | 4.8/10.8 |
| Cmax (μg/ml) | 6.5/14.7 | 14.9/18.0 | 10.3/14.2 | 10.6/15.6 |
| Cmax− Cmin/Cmin | 1.2/0.8 | 0.9/0.2 | 1.9/0.5 | 1.3/0.5 (before/6 months after EM) |
EM, erythromycin; %FEV1.0, % predict value of 1 second forced expiratory volume; CL, clearance; tl/2, half-time; AUC, area under the curve; C, concentration.